Site is Being Upgraded

A flu vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing Influenza A/flu(H1N1) vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Influenza A/flu(H1N1) vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via down regulation of its target gene, 12/July/2018, 1.04 pm

A flavonoid way to lengthen lifespan: Quercetin, a flavonoid isolated from elder berries, onions and others,  may  increase insulin sensitivity, slow down cardiac aging, and increase life span, via up-regulation of BubR1 and others genes, 12/July/2018, 12.53 pm
July 12, 2018
Inhibitors of heat shock response as longevity-promoters: 17-DMAG, a heat shock protein-90 (HSP-90) inhibitor, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 12/July/2017, 1.20 pm
July 12, 2018
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


From Research findings to Therapeutic opportunity:

This study suggests, first the first time, Influenza A/flu(H1N1) vaccine-based therapy, with detailed mechanistic insights, for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD) . Influenza A (H1N1)-vaccine  has been shown to protect against cardiovascular diseases, stroke, and others. However, the mechanism of action remains largely unknown.

Influenza A/flu(H1N1) vaccine, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Influenza/flu(H1N1) vaccine, either alone or in combination with other drugs,may be used to treat NAFLD.

Figure 1. Mechanistic insights into how  Influenza A/flu(H1N1) vaccine decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Repurposing Influenza/flu(H1N1) vaccine  into a cholesterol-lowering vaccine. Influenza/flu(H1N1) vaccine lowers cholesterol and triglyceride levels and attenuates NAFLD through down regulation of HMGCR

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Influenza A/flu(H1N1) vaccine decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., A flu vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing Influenza A/flu(H1N1) vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Influenza A/flu(H1N1) vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 12/July/2018, 1.04 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.